Bluebird Bio upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement ...
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
BioPharma Dive2d
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Bluebird Bio price target lowered to $5 from $40 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...
FiercePharma2d
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Once a darling of biotech, bluebird sells for less than $30M upfront
Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
The Morning Journal2d
Black River Audubon Society hosts talk by bluebird experts
Penny and Fritz Brandau, members of the Black River Audubon Society and the Ohio Bluebird Society, will give a presentation ...